Hormone replacement therapy combined with testosterone for the treatment of hypoactive sexual desire disorder in climacteric women

Terapia de reemplazo hormonal combinada con testosterona para el tratamiento del trastorno del deseo sexual hipoactivo en mujeres en climaterio

Objective: to evaluate the efficacy and safety of two hormone replacement therapies, combined with testosterone, in the treatment of hypoactive sexual desire disorder in women in climacteric. Materials and methods: clinical trial, randomized, controlled, not masked. Women over 40 years old and under 60 years old, with a uterus, with sexual activity in the last six weeks, suffering from vasomotor symptoms, whose reason for consultation consisted of low sexual desire were included. The Female Sexual Function Index questionnaire was used as an instrument. Two randomized groups were assigned: group "A" (51 received conjugated estrogens from equines and medroxyprogesterone plus testosterone) and group "B" (54 tibolone plus testosterone). The study was conducted between July 2015 and December 2016, in Armenia, Quindío, Colombia. Results: a population of 105 women was analyzed. The average age was 55,8 (SD ± 9,38) years. In the total population, at the beginning of the study, the median was 3 sexual encounters per month. In the end, the median was 5 sexual encounters per month, (group «A» 4 meetings and group «B» 7 meetings, p = 0,0036). At the end of the investigation, it was observed that the women of the «B» group showed significantly higher average scores in the IFSF (28,56 SD ± 4,63 points), compared with values ​​in the women of the «A» group (27,57 DS ± 4,32) (p <0,0001). Conclusions: testosterone-associated tibolone therapy is an effective treatment option in hypoactive sexual desire disorder in women in climacteric.